Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers

Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "JLP-2302" and "JP-1366" in Healthy Volunteers

This study aims to evaluate the pharmacokinetics and the safety after administration of "JLP-2302" and "JP-1366" in healthy volunteers.

Inclusion Criteria:

• Subjects with a body mass index (BMI) between 18.0 and 30.0 kg/m²
• Subjects without any clinically significant congenital or chronic disease, and with no pathological findings based on medical examination
• Subjects who agree to use a medically acceptable method of contraception*

Exclusion Criteria:

• Subjects who have taken enzyme-inducing or -inhibiting drugs
• Subjects who have participated in a bioequivalence or other clinical trial and received an investigational product within 6 months prior to the first dose
• Subjects with a history of gastrointestinal surgery that may affect drug absorption
• Subjects with a clinically significant history of psychiatric illness
• Female subjects who are pregnant, suspected of being pregnant, or currently breastfeeding